Scientists seek to improve quality control for genome editing therapies in the eye  

By Jordana Lenon, UW-Madison Stem Cell and Regenerative Medicine Center As gene editing therapies for macular degeneration and other visual disorders work their way into clinical trials, the University of Wisconsin–Madison is on the forefront of research into making sure they are safe and effective. Nine years ago, David Gamm, M.D., Ph.D., Director of the […]

Read the full article at: